Αρχική World News PROs Support Switching to Camizestrant Plus CDK4/6 Inhibitor for HR-positive, HER2-negative ABC... World News PROs Support Switching to Camizestrant Plus CDK4/6 Inhibitor for HR-positive, HER2-negative ABC and Emergent ESR1 Mutations During First-Line Endocrine-Based Therapy Από Ogkologos - 10 Νοεμβρίου, 2025 304 0 Facebook Twitter Google+ Pinterest WhatsApp Patient-reported outcomes from the SERENA-6 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Nivolumab and Relatlimab Combination Shows Promise in Advanced Melanoma 21 Ιουνίου, 2021 FDA Approves Retifanlimab-dlwr with Carboplatin and Paclitaxel and as a Single... 20 Ιουνίου, 2025 ESMO Congress 2022, 9-13 September 22 Αυγούστου, 2022 First-Line Treatment with Ribociclib plus Letrozole Shows a Significant Overall Survival... 22 Μαρτίου, 2022 Φόρτωση περισσοτέρων HOT NEWS 10 Tips for National Cancer Prevention Month Olivia Newton-John Puts On Iconic ‘Grease’ Costume And Talks About Cancer... ESMO Gynaecological Cancers Congress 2025, Vienna, Austria, 19-21 June ESMO Advocates for EU Legislation to Prevent Oncologist Burnout and Ensure...